ReviewJournal of multidisciplinary healthcare2025
Impact of Medications for Stable Angina Pectoris on Osteoporosis: A Review of Current Evidence.
Review in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adjunctive Use of Locally Delivered Statins in Periodontal Therapy and Pre-Implant Bone Regeneration: A Systematic Review and Meta-Analysis.Clinical and experimental dental research · 2026Pooled it
- Investigating the association between angina and osteoporosis: a 20-year longitudinal cohort study of ELSA.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stable angina pectoris (SAP) and osteoporosis (OP) are both prevalent conditions among the elderly population. Compared to SAP, the prevention and management of OP are often neglected. Furthermore, certain medications used long-term for SAP may exert significant effects on bone metabolism. This review summarizes the impact of commonly prescribed SAP medications on OP. Extensive research indicates that nitrates not only promote vascular and osteogenic coupling via the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) pathway, enhancing the osteogenic effects of estrogen and mechanical stimulation, but also regulate bone immunity through receptor-interacting protein kinase 3 (RIPK3), promoting bone remodeling. β-Blockers promote osteoblast proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) via the cAMP/PKA signaling pathway, stimulating bone formation, while concurrently inhibiting osteoclasts and reducing bone resorption. Statins, which inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase to regulate lipid metabolism, also upregulate bone morphogenetic protein 2 (BMP-2) expression, inducing osteogenic differentiation of BMSCs, and inhibit osteoclast differentiation and activity, thereby promoting bone formation and suppressing bone resorption. Aspirin (AS) activates osteoblasts and their precursor cells, stimulates angiogenesis, mitigates inflammatory responses, promotes bone regeneration, and accelerates bone repair. However, clopidogrel reduces osteoblast numbers via P2 receptor-mediated extracellular nucleotide signaling and promotes adipogenic differentiation of BMSCs; furthermore, its metabolism can decrease serum 25-hydroxyvitamin D levels, adversely affecting skeletal health. Calcium channel blockers (CCBs) exhibit a largely neutral effect on bone health in clinical evidence, although basic research suggests potential benefits. The heterogeneity in research findings profoundly reflects the complexity of bone metabolism and the limitations of current studies. Synthesizing the evidence, preferential consideration may be given to nitrates, β-blockers, statins, and aspirin for SAP patients with coexisting OP or at significant risk; when clopidogrel is used, enhanced monitoring of bone parameters and intensified prevention and treatment of OP are recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.